

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:  
Assistant Commissioner for Patents  
Washington, D.C. 20231

On 7-12-02

TOWNSEND and TOWNSEND and CREW LLP

By: Linda Shaffer



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:

Jonathan A. Ellman, *et al.*

Application No.: 09/534,706

Filed: March 23, 2000

For: METHODS FOR TREATING  
NEURODEGENERATIVE DISORDERS  
USING ASPARTYL PROTEASE  
INHIBITORS

Examiner: T. McKenzie

Art Unit: 1624

SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT UNDER 37  
CFR §1.97 and §1.98

COPY OF PAPERS  
ORIGINALLY FILED

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

The references cited on attached form PTO/SB/08B are being called to the attention of the Examiner. Copies of the references are enclosed. Also enclosed is a copy of the Supplementary European Search Report corresponding to the European application. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

PATENT  
Attorney Docket No.: 18062G-002010  
Client Reference No.: B99-070

RECEIVED

JUL 23 2002

TECH CENTER 1600/2900

#11 (B)  
7/27/2  
1624


COPY OF PAPERS  
ORIGINALLY FILED

Jonathan A. Ellman, *et al.*  
Application No.: 09/534,706  
Page 2

RECEIVED PATENT

JUL 23 2002

TECH CENTER 1600/2900




CERTIFICATION

I hereby certify that each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

Applicants believes that no fee is required for submission of this statement.

However, if a fee is required, the Commissioner is authorized to deduct such fee from the under the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

  
Eugenia Garrett-Wackowski  
Reg. No. 37,330

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, 8<sup>th</sup> Floor  
San Francisco, California 94111-3834  
Tel: 925 472-5000  
Fax: 925 472-8895  
EGW:lls

WC 9043679 v1